Early antiretroviral therapy prevents non-AIDS outcomes in HIV-infected people
21 July 2015
Starting antiretroviral therapy early not only prevents serious AIDS-related diseases, but also prevents the onset of cancer, cardiovascular disease, and other non-AIDS-related diseases in HIV-infected people, according to a new analysis of data from the Strategic Timing of AntiRetroviral Treatment (START) study, the first large-scale randomized clinical trial to establish that earlier antiretroviral treatment benefits all HIV-infected individuals.
Public markets still open to European biotech; IPO total tops $1.5B, so far
21 July 2015
Cell therapy firm Reneuron plc’s forthcoming £68.4 million (US$106 million) capital increase is further evidence of the continued buoyancy of the public funding environment for European biotech companies.
Price controls fail to improve poor people's access to medicines in India, IMS report says
21 July 2015
India's National Pharmaceutical Pricing Authority (NPPA) is busy on both the pharma and device fronts to bring down costs to consumers. But the efforts may do more harm than good, according to an industry-sponsored study by IMS Health Information and Consulting Services India.
Russian-Indian partnership to focus on diagnostics of hereditary diseases
21 July 2015
The ReadSense genome center based in Troitsk just outside Moscow and India’s Strand Life Sciences, a global leader in bioinformatics for personalized medicine, are pooling efforts in the development of tests for hereditary disease diagnostics, reported Rusnano, Russia’s largest nanotech company.
From the pharma C-suite: J&J on Asia, emerging markets in Q2
20 July 2015
FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan.
Blazing biotech IPO market continues to deliver a fortune for startups
20 July 2015
The go-go market for biotech IPOs is steaming ahead, pushing two more developers onto Nasdaq with a combined $239 million payoff at above-range prices. And biotech billionaire Patrick Soon-Shiong set a price range on his upcoming IPO for NantKwest at $20 to $23 a share, looking to raise around $160 million--or more--based on a company valuation of $2.2 billion.
Tufts: The vaccine pipeline is soaring and global sales could hit $40B by 2020
20 July 2015
The vaccine product pipeline has never been fuller, with more than triple the number of candidates in development today than in 2005 and global sales on track to reach $40 billion in five years, according to the July/August Impact Report from the Tufts Center for the Study of Drug Development (CSDD).
Patient in Siberia walks with new Russian nanoceramics hip; German market dominance to be challenged
20 July 2015
Surgeons in Novosibirsk, in Siberia, earlier this summer performed a successful implantation of a nanoceramics-based hip joint prosthesis in a 53-year-old male, Russia’s first such surgery ever. The Russian endoprosthesis has been produced by NEVZ-Ceramics, a local innovation company, the Russian news agency Interfax reported .
International project led by Russian scientist wins EU Nanotechnology Forum
17 July 2015
An international project led by a Russian scientist received the top award in the category of “Nanotechnology, New Materials and Production” at the most recent EU Nanotech Forum, Russia’s Sputnik News reported .
Pharma M&A shoots up to $159B for first half, but prices could dampen the mood
17 July 2015
Think last year was an M&A record-breaker in biopharma? 2015 is on track to top it, a new report says. According to Mergermarket, in the first 6 months of this year, global M&A activity in the pharma, medical and biotech industries hit its highest half-year value since 2001 with $211.2 billion worth of deals. That's a 2.7% boost from H1 2014's $205.7 billion mark.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024